Pfizer sues Metsera, Novo Nordisk
Digest more
NEW YORK, November 03, 2025--(BUSINESS WIRE)--Pfizer Inc. today announced that it has filed a second lawsuit against ...
Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO stock is a buy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results